ADRA2C and Alzheimer disease: In a randomized double-blind placebo-controlled exploratory phase 2a trial with 100 subjects with AD and neuropsychiatric symptoms, ORM-12741 (a selective antagonist of alpha-2C adrenoceptors, dosed at 30–60 mg or 100–200 mg, b.i.d for 12 weeks) administered in addition to standard therapy with cholinesterase inhibitors showed a statistically significant effect in Quality of Episodic Memory [86].